Frequently Asked Questions
The market is segmented based on , By Product (Clinical Laboratory Analysers and Point-Of-Care Testing Analysers), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Partial Thromboplastin Time Testing , Activated Clotting Time Testing , D-Dimer Testing, Platelet Function Tests , Anti-Factor Xa Tests, Heparin and Protamine Dose Response Tests for ACT and Others), Technology (Mechanical Technology, Optical Technology, Electrochemical Technology and Others), Application (Bleeding Disorders, Acquired Bleeding Disorders, Von Willebrand Disease and Haemophilia), End User (Academic Institutions, Hospitals, Diagnostic Laboratories and Others) – Industry Trends and Forecast to 2030.
.
The Global Blood Clotting Factor Market size was valued at USD 5687.25 USD Million in 2022.
The Global Blood Clotting Factor Market is projected to grow at a CAGR of 8.7% during the forecast period of 2023 to 2030.
The major players operating in the market include CSL Behring, Shire, Novo Nordisk, Grifols, Octapharma, Pfizer , Ferring Pharmaceuticals, Kedrion Biopharma, Bayer AG, BioMarin Pharmaceutical, Sanquin, LFB Group, Bio Products Laboratory, Hualan Biological Engineering, GC Pharma.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
